Lisata Therapeutics Inc investor relations material

Listen to the latest call from Lisata Therapeutics Inc

Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing cellular therapies to reverse disease, promote regeneration and halt disease progression. Its product candidates include HONEDRA, a cell therapy product candidate that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; CLBS201, a CD34+ cell therapy for pre-dialysis patients with chronic kidney disease; AB1250-H, an investigational drug product candidate for acute myocardial infarction (AMI) patients who have undergone percutaneous coronary intervention (PCI); and VB6100, an investigational gene therapy product candidate designed to treat demyelinating disorders such as multiple sclerosis

Upcoming events

Previous events

Dig deeper into the Lisata Therapeutics Inc fundamentals on Quartr.